专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07361330B2 Methods of using flt3-ligand in the treatment of fibrosarcoma 失效
标题翻译：使用flt3-配体治疗纤维肉瘤的方法
公开(公告)号：US07361330B2
公开(公告)日：2008-04-22
申请号：US10241927
申请日：2002-09-11
申请人： David H. Lynch , Luis Borges , Robert E. Miller , Charles R. Maliszewski
发明人： David H. Lynch , Luis Borges , Robert E. Miller , Charles R. Maliszewski
IPC分类号： A61K38/19
CPC分类号： C12N5/0639 , A61K38/18 , A61K39/0011 , A61K39/39 , A61K2039/505 , A61K2039/5154 , A61K2039/55516 , A61K2039/55522 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/26 , C12N2506/30 , A61K2300/00
摘要： Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.
摘要翻译：公开了使用flt-3配体治疗纤维囊瘤的方法，以及增加患有纤维肉瘤的患者中树突状细胞数量的方法。

2. 发明申请

US20050238643A1 Modulation of lir function to treat rheumatoid arthritis 审中-公开
标题翻译：调节lir功能治疗类风湿关节炎
公开(公告)号：US20050238643A1
公开(公告)日：2005-10-27
申请号：US10495695
申请日：2002-11-12
申请人： Jonathan Arm , Nicodemus Tedla , Luis Borges
发明人： Jonathan Arm , Nicodemus Tedla , Luis Borges
IPC分类号： A61K45/00 , A61K39/395 , A61K45/06 , A61P29/00 , A61P43/00 , C07K16/28
CPC分类号： C07K16/2803 , A61K2039/505
摘要： This invention relates to methods for treating rheumatoid arthritis (RA) by administering one or more agents that specifically target LIR-2, LIR-3 and LIR-7. Results disclosed herein indicate that these three LIRs may participate in regulating the activation of leukocytes that infiltrate synovial tissue. Thus, inflammation in the joints of RA patients can be ameliorated by administering agents that modulate expression or function of LIR-2 and/or LIR-3 and/or LIR-7 to reduce or eliminate the activation of monocytes or macrophages present in inflamed joints, or to reduce their recruitment to the site of inflammation. This can be accomplished by modulating LIR-7, which transmits a stimulatory signal, and/or by modulating LIR-2 and/or LIR-3, which when triggered exert an inhibitory effect, or by concurrently modulating two or all three of these LIRs.
摘要翻译：本发明涉及通过施用一种或多种特异性靶向LIR-2，LIR-3和LIR-7的试剂来治疗类风湿性关节炎（RA）的方法。本文公开的结果表明，这三种LIR可参与调节渗透滑膜组织的白细胞的活化。因此，RA患者关节炎症可以通过调节LIR-2和/或LIR-3和/或LIR-7的表达或功能的给药剂来改善，以减少或消除发炎关节中存在的单核细胞或巨噬细胞的活化，或减少他们招募到炎症部位。这可以通过调节传递刺激信号的LIR-7和/或通过调节LIR-2和/或LIR-3来实现，其在触发时发挥抑制作用，或通过同时调节这些LIR中的两个或所有三个。

3. 发明申请

US20070025993A1 Tek antagonists 审中-公开
标题翻译： Tek拮抗剂
公开(公告)号：US20070025993A1
公开(公告)日：2007-02-01
申请号：US11416613
申请日：2006-05-02
申请人： Douglas Cerretti , Luis Borges , William Fanslow
发明人： Douglas Cerretti , Luis Borges , William Fanslow
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K14/475 , C07K16/22
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00 , C07K2319/02
摘要： The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
摘要翻译：本发明通过施用Tek拮抗剂来提供Tek拮抗剂和抑制哺乳动物血管生成的方法。该方法特别可用于治疗由血管发生介导的疾病或病症，例如实体瘤和以眼新生血管形成为特征的疾病或病症。

4. 发明申请

US20060292166A1 Vaccine composition comprising Flt3-ligand 审中-公开
标题翻译：包含Flt3-配体的疫苗组合物
公开(公告)号：US20060292166A1
公开(公告)日：2006-12-28
申请号：US11510651
申请日：2006-08-28
申请人： David Lynch , Luis Borges , Robert Miller , Charles Maliszewski
发明人： David Lynch , Luis Borges , Robert Miller , Charles Maliszewski
IPC分类号： A61K39/12 , A61K39/02 , A61K39/00
CPC分类号： C12N5/0639 , A61K38/18 , A61K39/0011 , A61K39/39 , A61K2039/505 , A61K2039/5154 , A61K2039/55516 , A61K2039/55522 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/26 , C12N2506/30 , A61K2300/00
摘要： Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.
摘要翻译： Flt3-配体可用于从造血祖细胞和干细胞产生大量的树突状细胞。 Flt3-配体可用于增加体内的免疫应答，并离体扩展树突状细胞。然后可以使用这种树突状细胞将肿瘤，病毒或其他抗原呈递给初始T细胞，可用作疫苗佐剂。当使用flt3-L和/或与其它反应剂组合施用时， CD40结合蛋白，4-1BBL或与4-1BB，CD30配体拮抗剂，RANKL和/或干扰素α反应的抗体组合进一步增强免疫应答和疫苗佐剂的有效性。

5. 发明申请

US20080102065A1 Erythropoietin receptor extended duration limited agonists 审中-公开
标题翻译：红细胞生成素受体延长持续时间有限的激动剂
公开(公告)号：US20080102065A1
公开(公告)日：2008-05-01
申请号：US11787181
申请日：2007-04-13
申请人： Luis Borges , Graham Molineux
发明人： Luis Borges , Graham Molineux
IPC分类号： A61K39/395 , A61P7/06 , C07K16/18
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2317/75 , C07K2317/92
摘要： A genus of erythropoietin (Epo) receptor agonists having unique structural, biochemical, and physiological characteristics has been discovered and is referred to herein as Erythropoietin Receptor extended Duration Limited Agonist (EREDLA).
摘要翻译：已经发现了具有独特结构，生物化学和生理学特征的红细胞生成素（Epo）受体激动剂属，在本文中被称为红细胞生成素受体延长持续时间限制激动剂（EREDLA）。

6. 发明申请

US20050173780A1 Circuit materials, circuits, multi-layer circuits, and methods of manufacture thereof 有权
标题翻译：电路材料，电路，多层电路及其制造方法
公开(公告)号：US20050173780A1
公开(公告)日：2005-08-11
申请号：US11039378
申请日：2005-01-19
申请人： Murali Sethumadhavan , Vincent Landi , Luis Borges
发明人： Murali Sethumadhavan , Vincent Landi , Luis Borges
IPC分类号： C08G77/04 , H05K1/03 , H05K3/46 , H01L23/58 , H01L21/4763
CPC分类号： H05K1/032 , H05K1/0366 , H05K3/4626 , H05K2201/0162 , H05K2201/0212 , Y10T428/31663
摘要： An electrical circuit material having a conductive layer disposed a substrate, wherein the substrate comprises an organic or inorganic polymer comprising a covalently bound polyhedral silsesquioxane (POSS). The substrate may further comprise an additional dispersed POSS, any other fillers including fibrous webs. Use of covalently bound POSS allows for flame retardancy in compositions having acceptable dielectric constants and dissipation factors.
摘要翻译：一种具有设置在基底上的导电层的电路材料，其中所述基底包含包含共价结合的多面体倍半硅氧烷（POSS）的有机或无机聚合物。基材还可以包含另外的分散POSS，任何其它填料，包括纤维网。使用共价结合的POSS可以在具有可接受的介电常数和耗散因子的组合物中具有阻燃性。

7. 发明授权

US5969206A Reverse emulsion aliphatic alkylation process with catalyst-olefin premixing 失效
标题翻译：反相乳液脂肪族烷基化方法与催化烯烃预混合
公开(公告)号：US5969206A
公开(公告)日：1999-10-19
申请号：US785041
申请日：1997-01-17
申请人： Jacques Alagy , Jean-Francois Joly , Eric Benazzi , Jean-Charles Viltard , Luis Borges , Alain Forestiere
发明人： Jacques Alagy , Jean-Francois Joly , Eric Benazzi , Jean-Charles Viltard , Luis Borges , Alain Forestiere
IPC分类号： C07C2/76 , C07B61/00 , C07C2/62 , C07C9/16 , C07C9/21 , C10G35/06 , C10G35/10 , C07C2/58
CPC分类号： C07C2/62 , C07C2527/054 , C07C2527/1206
摘要： The invention concerns a process for the alkylation of at least one isoaffin selected from the group formed by isobutane and isopentane by at least one olefin containing 2 to 6 carbon atoms per molecule in the presence of a liquid acid catalyst, the process comprising mixing a feed comprising the olefin to be converted with an effluent comprising a major portion of isoparaffin in a first mixing zone, and forming an emulsion of said catalyst in a hydrocarbon effluent comprising a major portion of isoparaffin in an emulsifying zone, said effluent constituting the continuous phase of the emulsion thus formed, then mixing a major portion of the emulsion of acid in hydrocarbon effluent with a major portion of the diluted feed comprising the olefin in a second mixing zone, followed by carrying out the majority of the reaction in a reaction zone which is supplied by the major portion of said mixture.
摘要翻译：本发明涉及在液体酸催化剂存在下，通过至少一种含有2-6个碳原子的烯烃在异丁烷和异戊烷中形成的至少一种异构烷烃的烷基化方法，该方法包括混合进料包括在第一混合区域中用包含大部分异链烷烃的流出物转化的烯烃，并且在包含乳化区中的主要部分异链烷烃的烃流出液中形成所述催化剂的乳液，所述流出物构成连续相由此形成的乳液，然后将大部分酸性乳液在烃流出物中与主要部分的稀释进料在第二混合区中混合，然后在反应区中进行大部分反应，反应区是由所述混合物的主要部分供应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式